













doi:10.101A Deletion Polymorphism in Glutathione-S-Transferase
Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an
Increased Risk of Toxicity after Autologous Blood and
Marrow Transplantation
Theresa Hahn,1 Eugenia Zhelnova,4 Lara Sucheston,2 Irina Demidova,4 Valery Savchenko,4
Minoo Battiwalla,1 Shannon L. Smiley,1 Christine B. Ambrosone,3 Philip L. McCarthy, Jr.,1Toxicity after blood and marrow transplantation (BMT) has interindividual variability that may be explained
by common genetic polymorphisms in critical pathways. The glutathione-S-transferase (GST) isoenzymes de-
toxify the reactive oxygen species generated by chemotherapy agents and radiation. We investigated
whether deletion polymorphisms in 2 GST genes (GSTM1 and GSTT1) were associated with toxicity after
autologous or allogeneic BMT. The study population was selected from 699 consecutive BMT patients
from 2 centers in Buffalo, NY, and Moscow, Russia, of whom 321 (203 autologous, 118 allogeneic BMT)
had available banked samples and amplifiable DNA. Fifty percent of patients were homozygous null for
GSTM1, which did not vary by center; however, the GSTT1 homozygous null deletion polymorphism
occurred more frequently in patients treated in Moscow (38% versus 18%, P\.001). Overall grade 2-4 reg-
imen-related toxicity occurred in 56%, with nearly 1 in 5 patients having 2 or more organ systems affected.
Among autologous BMT patients, a deletion polymorphism in 1 or both genes was significantly associated
with increased occurrence of overall toxicity (71% versus 56%, P 5 .034) and mucositis (74% versus 55%,
P 5 .006). GSTM1 and/or GSTT1 deletion polymorphisms were not associated with toxicity after allogeneic
BMT. Future studies may allow for individualized genetic risk stratification.
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Blood and marrow transplant (BMT) patients are
a unique patient population at high risk for treat-
ment-induced morbidity and mortality. Prediction
of toxic morbidity has been infrequently studied de-
spite a major impact on patient quality of life and health
care resource utilization. Toxicity after BMT has inter-
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(ROS) generated by chemotherapeutic agents and radi-
ation can damage cells, proteins, and DNA, or interact
with other cellular molecules, producing secondary re-
active oxidation products, all of which can contribute
to organ toxicity [1–3].
The phase II detoxification enzymes include gluta-
thione S-transferases (GSTs), which consists of several
isoenzyme classes, including: mu (GSTM1), pi
(GSTP1), alpha (GSTA1), theta (GSTT1), and zeta
(GSTZ1). The genes for these enzymes are located on
chromosomes 1p13.3 (GSTM1), 22q11.23 (GSTT1),
11q13 (GSTP1), 6p12.1 (GSTA1), and 14q24.3
(GSTZ1). The GST isoenzymes neutralize the ROS
generated by most chemotherapeutic agents and radi-
ation [1,4-8]. Phase II detoxification enzymes are
polymorphic, which may contribute to the interindi-
vidual variability in the response to oxidative stress
and the development of BMT regimen-related toxic-
ity (RRT). The GSTM1 and GSTT1 genes exhibit
a common deletion polymorphism that results in no
enzyme activity [9,10].801
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relationship ofGSTM1-null genotype and toxicity after
BMT, with conflicting results. One study described an
increased incidence of hepatic veno-occlusive disease
after busulfan (Bu) 1 cyclophosphamide (Cy) condi-
tioning for allogeneic BMT in GSTM1-null patients
treated for b-thalassemia major in India [11]. However,
a similar study in German and Italian allogeneic BMT
recipients did not find an association between GSTM1
polymorphisms and liver toxicity after Bu1 Cy condi-
tioning [12]. A Japanese study found a decreased risk of
treatment-related mortality and improved overall sur-
vival (OS) after unrelated donor allogeneic BMT in
GSTM1-null patients [13]. In the nontransplant setting,
GSTM1-null genotype has been associated with an in-
creased risk for hepatotoxicity in Japanese patients
treated with carbamazepine [14] or valproic acid [15],
and with 1 study in Spanish patients, [16] suggesting
an increased risk of drug-induced liver injury in
GSTM1 null genotypes for all drugs.
As summarized above, GSTM1 and GSTT1 geno-
types have been studied in relation to hepatic toxicity
after allogeneic BMT with varying results. However,
the relative contribution of GSTM1 and GSTT1 null
genotypes to overall RRT postallogeneic BMT, and
to any toxicity postautologous BMT, have not been
studied. Therefore, we performed a candidate gene
study to determine if GSTM1 and GSTT1 polymor-
phisms were associated with overall moderate, severe,
or fatal RRT after autologous and allogeneic BMT.METHODS
Study Population
The population was selected from 699 consecutive
first autologous and allogeneic BMTs performed at
Roswell Park Cancer Institute (RPCI) in Buffalo,
NY, from 1/1/1996 to 12/31/2002 (N 5 496) or
National Research Center for Hematology (NRCH)
in Moscow, Russia, from 1/1/1996 to 12/31/2006
(N 5 203). Exclusion criteria were: prior autologous
or allogeneic BMT, cord blood transplant, and no
banked sample. Underrepresented BMT conditioning
regimen groups (n \ 10 patients) were excluded to
reduce heterogeneity of the population. Fifty-one per-
cent of the original cohort (N5 356 patients) had pro-
cured samples available in a biospecimen repository, of
which 321 (90% of stored samples) yielded amplifiable
DNA. Paired donor samples were not available in the
allogeneic BMT patients.Patient Treatment
Conditioning and high-dose therapy regimens
varied by center. At RPCI, they included (Cy 1 total
body irradiation (TBI) 6 etoposide (V) (n 5 61),melphalan (Mel)6 TBI (n5 60), thiotepa (Tt)1 car-
boplatin (Cp) 6 Cy (n 5 49), Tt 1
TBI (n 5 38), Bu 1 Cy (n 5 29), C 1 carmustine
(B) 1 V (n 5 18) and Bu 1 V (n 5 13). At NHRC,
they included Bu 1 Cy (n 5 31), fludarabine 1 Bu 1
other (n 5 11), B 1 V 1 cytarabine 1 Mel (n 5 6)
or Mel (n 5 5). GVHD prophylaxis regimens at
RPCI were calcineurin inhibitor 1 methotrexate
(MTX) (n 5 33), calcineurin inhibitor 1 methylpred-
nisolone (MP)1OKT3 (anti-CD3 antibody) (n5 19),
calcineurin inhibitor1MTX1MP (n5 17), or other
(n 5 9). Graft-versus-host disease (GVHD) prophy-
laxis regimens at NHRC were calcineurin inhibitor
1 MTX (n 5 22), calcineurin inhibitor 1 MTX 1
prednisone (n 5 15), and calcineurin inhibitor 1
MTX 1 mycophenylate mofetil (n 5 3).
Study Conduct
All patients signed informed consent for procure-
ment of specimens and treatment with BMT at each
center. All clinical data and biospecimens from
NRCH were deidentified before transfer to RPCI. In
addition, this research study was approved by RPCI’s
institutional review board as a nontherapeutic protocol
with collection and analysis of existing clinical data and
banked specimens. Genotyping of all patient samples
and all statistical analyses were performed at RPCI.
Genotyping
Peripheral blood or BM samples were drawn be-
fore BMT and had been stored in liquid nitrogen for
up to 10 years. DNA was extracted from these thawed
samples using Gentra Puregene DNA isolation kits,
according to the manufacturer’s instructions. DNA
quantification used the Pico-Green immunofluores-
cence method.
The GSTM1 and GSTT1 gene deletions were ex-
amined by multiplex polymerase chain reaction
(PCR), as previously reported [17]. Briefly, amplifica-
tion consisted of a denaturation step at 94C for 4
minutes, annealing at 94C for 30 seconds, 64C for
30 seconds, and 72C for 30 seconds for 30 cycles,
and polymerization at 72C for 7 minutes for 1 cycle.
Forward and reverse primers for GSTM1 were GAA
CTCCCTGAAAAGCTAAAGC and GTTGGGC
TCAAATATACGGTGG and for GSTT1 were TTC
CTTACTGGTCCTCACATCTC and TCACCG
GATCATGGCCAGCA. The GSTM1 fragment has
a length of 215 bp; the GSTT1 fragment has a length
of 489 bp. Human albumin was used as the positive
control with forward and reverse primers of GCC
CTCTGCTAACAAGTCCTAC and GCCCTAAA
AAGAAAATCGCCAATC and has a fragment of
351 bp. Each 50-mL PCR reaction contained 5 mL of
10 PCR buffer, 5 mL of 25 mM MgCl2, 1 mL of 10
mM deoxynucleotides (ACGT), 1 mL of each primer
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mL of forward and reverse primers for human albumin,
26.36 mL of ddH2O, 0.44 mL Taq, 1.76 mL TaqStart
buffer, 0.44 mL TaqStart antibody, and 5 mL of un-
known sample DNA. PCR products were visualized
by agarose gel (2%) electrophoresis. This assay does
not distinguish between heterozygous and homozy-
gous presence of either gene; therefore, patients are
designated either ‘‘homozygous null’’ or ‘‘heterozy-
gous/homozygous present.’’ All plates contained
blinded duplicates and positive and negative controls
for quality control.
Gene Frequencies
Previously reported frequencies in a large analysis
of over 15,000 healthy noncancer controls were 53.1%
in Whites, 52.9% in Asians, and 26.7% in Africans for
the GSTM1 homozygous null genotype; 19.7% in
Whites and 47% in Asians for the GSTT1 homozy-
gous null genotype; and 10.4% in Whites and 24.6%
in Asians for both the GSTM1 and GSTT1 null geno-
types [18]. In addition, GSTM1 and GSTT1 null geno-
types have been shown to have considerable variability
within White persons from different countries in
North America, Europe, and the Middle East, ranging
from 46.9% to 58.3% for GSTM1 and 12.9% to
27.6% for GSTT1. Several other reports have de-
scribed variability within the ethnic subpopulations
of several countries [19-21]. The differences in poly-
morphism frequencies between ethnic groups are
well described as noted previously, but we did not
exclude non-White ethnicities from this study. Al-
though the frequency of the null genotype varies by
ethnicity, the phenotype-genotype relationship, that
is, the absence of enzyme activity with the presence
of a null deletion polymorphism, remains constant
regardless of ethnicity.
Definition of RRT
RRT was the primary outcome defined according
to published criteria [22] and dichotomized to grade
0-1 in all organs versus grade 2-4 in any 1 or more or-
gan systems. The observation time for RRT started
with the first dose of the conditioning or high-dose
therapy regimen until day 1100 after infusion of the
hematopoietic stem cells. The focus of this study was
grade 2 (moderate, requiring medical intervention),
grade 3 (severe, life-threatening), and grade 4 (fatal)
toxicity. Grade 1 RRT is self-limiting, does not require
any medical intervention, and was therefore not in-
cluded in the definition of the main outcome variable.
In allogeneic BMT patients, there may be difficulty
differentiating RRT from acute GVHD (aGVHD)
or other complications in the early post-BMT period.
Therefore, once aGVHD was diagnosed, the patient
was no longer evaluated for RRT in the hepatic orgastrointestinal (GI) organ systems; however, other or-
gan systems not usually affected by aGVHD, namely
cardiac, bladder, pulmonary, renal, central nervous
system (CNS), and mucositis, were still evaluable for
RRT. Similarly, if a positive culture was obtained
within 4 days of clinically significant symptoms, then
they were attributed to infection and not RRT. Hence,
there may be underreporting of RRT, which increases
type II error by attenuating the effect size of the pri-
mary outcome and biasing the results toward the null
hypothesis. In addition, autologous BMT patients
serve as a comparison group because there is a much
lower rate of infectious complications and no aGVHD
to confound the diagnosis of RRT.Definition of Disease Status
Disease status at time of BMT was defined as
early (first complete remission or chronic phase), inter-
mediate (second or greater complete remission or
chronic phase or first partial remission), or late (re-
lapsed or refractory active disease with less than a par-
tial response to the most recent chemotherapy regimen
pre-BMT).Statistical Analysis
This study was designed as a hypothesis generating
study with the a priori null hypothesis that deletion
polymorphisms in GSTM1 and/or GSTT1 were not
associated with grade 2-4 RRT after autologous or al-
logeneic BMT. The NHRC study population was too
small to use as an independent validation cohort;
therefore, the 2 centers were pooled to provide the
largest possible discovery cohort. Descriptive and uni-
variate analyses used the Pearson chi-square test.
Given the significant differences between the 2 centers
on patient and treatment characteristics, the Fisher’s
combined P-value was calculated for all analyses in-
cluding both centers. Univariate analysis used logistic
regression with outcome defined as grade 2-4 toxicity
in 1 or more organs by day 100 as the primary out-
come. Secondary analyses of the most common organ
sites (mucositis and renal toxicity) were also con-
ducted. Survival curves were generated using the Ka-
plan-Meier method and compared using the log-rank
test. Overall survival (OS) was defined as time from
date of BMT to last follow-up (censored) or death
because of any cause (event). Because of the small het-
erogenous population, 2-sided P\ .05 was considered
statistically significant, and P. .05 to\.1 was consid-
ered a trend. There was no correction for multiple test-
ing. Post hoc power calculations indicated that an
effect size of $2.5 was detectable in the allogeneic
BMT population and $1.75 was detectable in the
autologous BMT population.











Median (range) Age, years 45 (11-72) 47 (11-72) 29 (16-63) <.001
Age, years <.001
<40 117 (36%) 80 (30%) 37 (70%)
40+ 204 (64%) 188 (70%) 16 (30%)
Male 168 (52%) 135 (50%) 33 (62%) NS
Race <.001
White 292 (91%) 252 (94%) 40 (76%)
Asian 13 (4%) 0 13 (24%)
African American 13 (4%) 13 (5%) 0
Hispanic 1 (<1%) 1 (<1%) 0
Diagnosis <.001
ALL/AML 85 (26%) 62 (23%) 23 (43%)
Breast Cancer 39 (12%) 39 (15%) 0
CML 30 (9%) 16 (6%) 14 (26%)
HL/NHL 103 (32%) 97 (36%) 6 (11%)
MDS/MPD 8 (2%) 3 (1%) 5 (9%)
MM 50 (16%) 46 (17%) 4 (8%)
Other 6 (2%) 5 (2%) 1 (2%)
Disease Status .001
Early 109 (34%) 150 (56%) 39 (74%)
Intermediate 49 (15%) 38 (14%) 11 (21%)
Advanced 83 (26%) 80 (30%) 3 (6%)
Donor Source
Autologous 203 (63%) 190 (71%) 13 (25%)
Related Allogeneic 102 (32%) 62 (23%) 40 (75%)
Unrelated Allogeneic 16 (5%) 16 (6%) 0 <.001
Stem Cell Source <.001
Bone Marrow 131 (41%) 93 (35%) 38 (72%)
Peripheral Blood 190 (59%) 175 (65%) 15 (28%)
Regimen Intensity <.001
Myeloablative 310 (97%) 268 (100%) 42 (79%)
Reduced Intensity 11 (3%) 0 11 (21%)
Total Body Irradiation <.001
Yes 135 (42%) 135 (50%) 0




90-100 220 (69%) 203 (76%) 17 (32%)
80 or less 101 (31%) 65 (24%) 36 (68%)
GSTM1 NS
Present 162 (50%) 138 (52%) 24 (45%)
Null 159 (50%) 130 (49%) 29 (55%)
GSTT1 .002
Present 251 (78%) 218 (81%) 33 (62%)
Null 70 (22%) 50 (19%) 20 (38%)
RPCI indicates Roswell Park Cancer Institute, Buffalo, NY; NRCH,National Research Center for Hematology, Moscow, Russia; ALL, acute lymphoblastic
leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MDS, mye-
lodysplastic syndrome; MPD, myeloproliferative disorder; MM, multiple myeloma; NS, not significant, P > .05.
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Center Characteristics and Toxicity Outcomes
Patient characteristics for the 2 centers are listed in
Table 1. There were statistically significant differences
between the 2 centers for most patient and treatment
characteristics. However, as shown in Table 2, the over-
all rate of RRT was 56% but was more common in the
NRCH group (70% versus 54%, NRCH versus
RPCI, respectively, P . .1). Of note, almost 1 in 5 pa-
tients developed RRT in 2 or more organ systems. Mu-
cositis was the most common organ toxicity (46% of all
patients), followed by renal (13%), cardiac (7%), pulmo-
nary (5%), and gastrointestinal (5%). Bladder, hepatic,
and CNS toxicity occurred infrequently (\5% each).Genotype Frequencies
The GSTM1 and GSTT1 null genotypes did not
significantly differ by sex. The frequency of the
GSTM1 null genotype did not vary between centers
(55% and 49%, NRCH versus RPCI, respectively);
however, the GSTT1 null genotype was significantly
more common in the NRCH group (38% versus
18%, P \ .001) and approached what has been re-
ported in Asian populations [18].Univariate Analysis of Toxicity
Table 3 summarizes the univariate analysis for au-
tologous BMT patients from both centers. KPS #80
(P 5 .004) and occurrence of the null genotype at
Table 2. Rate of Grade 2-4 Regimen-Related Toxicity by Center










In any 1 or more organ systems 144 (54%) 37 (70%) 181 (56%)
Total number of organ systems
0 124 (46%) 16 (30%) 140 (44%)
1 102 (38%) 21 (40%) 123 (38%)
2 27 (10%) 10 (19%) 37 (12%)
3 3 (1%) 2 (4%) 5 (2%)
4 10 (4%) 3 (6%) 13 (4%)
5 1 (<1%) 1 (2%) 2 (<1%)
6 1 (<1%) 0 1 (<1%)
Mucositis 114 (43%) 34 (64%) 148 (46%)
Renal 31 (12%) 10 (19%) 41 (13%)
Cardiac 21 (8%) 2 (4%) 23 (7%)
Pulmonary 16 (6%) 0 16 (5%)
Gastrointestinal 8 (3%) 8 (15%) 16 (5%)
Central nervous system 13 (5%) 1 (2%) 14 (4%)
Hepatic 7 (3%) 6 (11%) 13 (4%)
Bladder 7 (3%) 3 (6%) 10 (3%)
RPCI indicates Roswell Park Cancer Institute, Buffalo, NY; NRCH, National Research Center for Hematology, Moscow, Russia.
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icantly increased risk for grade 2-4 RRT. The unad-
justed relative risk for grade 2-4 RRT after
autologous BMT with the null genotype at GSTM1,
GSTT1, or both was 1.87 (95% confidence interval
[CI] 1.04-3.32, P 5 .035, Table 4) and after adjusting
for KPS increased to 1.95 (95% CI 1.08-3.54, P 5
.027). For allogeneic BMT, only race was significantly
associated with grade 2-4 RRT, with a higher rate of
toxicity in non-White patients (95% versus 82%
White for grade2-4 RRT, P 5 .047). The unadjusted
relative risk for grade 2-4 RRT after allogeneic BMT
with the null genotype at GSTM1, GSTT1, or both
was 1.26 (95% CI 0.57-2.75, P . .1).
Grade 2-4 mucositis was the most common RRT
occurring in 78% (89/114) of autologous BMT pa-
tients. In this subgroup, KPS #80 was more common
in those with mucositis (38% versus 24%, P5 .025), in
addition to the GSTM1 null genotype (55% ver-
sus42%, P 5 .067) and the occurrence of a null geno-
type at either GSTM1 and/or GSTT1 (74% versus
55%, P5 .006). The unadjusted relative risk for grade
2-4 RRT after autologous BMT with the null geno-
type at GSTM1, GSTT1, or both was 2.32 (95% CI
1.27-4.24, P 5 .006). Both KPS (relative risk [RR] 5
2.09, 95% CI 1.12-3.89, P 5 .02) and the null geno-
type at GSTM1, GSTT1 or both (2.41, 95% CI 1.31-
4.44, P 5 .005) were significant predictors of grade
2-4 mucositis after autologous BMT.
Survival Analysis
Median follow-up in the survivors is 4.3 years
(range: 0.04-13.1 years). OS was not significantly
different by the presence or absence of a deletion poly-
morphism in GSTM1, GSTT1, or any combination of
the 2 genes. After stratifying by donor type, autologousBMT patients with the null genotype at both GSTM1
and GSTT1 had a nonsignificantly lower 4-year OS
(22%, 95% CI 0%-49%) than those with only 1
(40%, 95% CI 31%-50%) or zero null genotypes
(45%, 95% CI 33%-57%) (P 5 .58, Figure 1A). In
contrast, allogeneic BMT patients with the null geno-
type at bothGSTM1 andGSTT1had a nonsignificantly
higher 4-year OS (53%, 95% CI 21%-84%) than
those with only 1 (43%, 95% CI 29%-57%) or zero
null genotypes (42%, 95% CI, 26%-58%) (P 5 .6,
Figure 1B).DISCUSSION
This is the first study of genetic polymorphisms
and toxicity after autologous BMT, the first report of
a significant association of polymorphisms and toxicity
after autologous BMT, and the first report of overall,
in addition to organ-specific (eg, mucositis, hepatic,
bladder, cardiac, etc.), toxicity. Our finding of
GSTM1 deletion polymorphisms conferring higher
risk of toxicity after autologous BMT contrasts with
2 prior reports showing increased risk of toxicity and
reduced survival with the null GSTT1 genotype in pe-
diatric [23] and adult [24] acute myelogenous leukemia
(AML) patients treated with lower dose chemotherapy.
The higher dose of chemotherapy used with autolo-
gous BMT and our more heterogeneous population
treated for a variety of hematologic diseases may be
the reason for this difference.
Rocha et al. [25] recently reported a study of 107
related allogeneic BMT patients that showed no asso-
ciation of GSTM1 and/or GSTT1 deletion polymor-
phism with several organ-specific toxicities including
mucositis, hemorrhagic cystitis, and hepatic veno-
occlusive disease, as well as no association with
Table 3. Univariate Analysis of Risk Factors for Grade 2-4





N 5 105 P
Center .06*
RPCI 95 (97%) 95 (91%)
NRCH 3 (3%) 10 (10%)
Gender NS
Male 50 (51%) 43 (41%)
Female 48 (49%) 62 (59%)
Age NS
$40 years 68 (69%) 78 (74%)
<40 years 30 (31%) 27 (26%)
Race NS
White 91 (93%) 99 (94%)
Asian 0 1 (1%)
African American 6 (6%) 4 (4%)
Other 1 (1%) 1 (<1%)
KPS .004
#80 20 (20%) 41 (39%)
90-100 78 (80%) 64 (61%)
Diagnosis NS
ALL/AML 11 (11%) 17 (16%)
Breast Cancer 19 (19%) 20 (19%)
CML 1 (1%) 0
HL/NHL 44 (45%) 39 (37%)
MM 20 (20%) 27 (26%)




Early 54 (55%) 69 (66%)
Intermediate 15 (15%) 13 (12%)
Advanced 29 (30%) 23 (22%)
Stem cell source NS
Bone marrow 18 (18%) 13 (12%)
Peripheral blood 80 (82%) 92 (88%)
Total-body irradiation NS*
Yes 31 (32%) 43 (41%)
No 67 (68%) 62 (59%)
GSTM1 NS
Present 57 (58%) 49 (47%)
Null 41 (42%) 56 (53%)
GSTT1 NS
Present 80 (82%) 82 (78%)
Null 18 (18%) 23 (22%)
GSTM1 and GSTT1
Either/both present 94 (96%) 100 (95%)
Both null 4 (4%) 5 (5%) NS
GSTM1 and GSTT1 .034
Both present 43 (44%) 31 (30%)
Either/both null 55 (56%) 74 (71%)
P indicates Fisher’s combined P-value across each center, except when
noted by *, which is the P-value from the Pearson chi-square test; NS,
not significant P > .1. Percentages may not add up to 100% because of
rounding; RPCI, Roswell Park Cancer Institute, Buffalo, NY; NRCH,
National Research Center for Hematology, Moscow, Russia; RRT, regi-
men-related toxicity; BMT, bone marrow transplantation; ALL, acute lym-
phoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic
myelogenous leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lym-
phoma; MDS, myelodysplastic syndrome; MPD, myeloproliferative disor-
der; MM, multiple myeloma; see Methods for definition of disease status.
Table 4. Relative Risk Estimates for Grade 2-4 RRT by
Genotype in Autologous and Allogeneic BMT Patients




Null 1.59 0.91-2.77 NS
GSTT1
Present 1.0
Null 1.25 0.63-2.48 NS
GSTM1+/-GSTT1
Both present 1.0




Null 1.36 0.64-2.89 NS
GSTT1
Present 1.0
Null 0.72 0.31-1.70 NS
GSTM1+/-GSTT1
Both present 1.0
Either/both null 1.26 0.57-2.75 NS
RR indicates relative risk; RRT, regimen-related toxicity; CI, confidence
interval.
*NS, not significant P > .1.
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Although our study in 118 allogeneic BMT patients
confirms the earlier Rocha et al. [25] and Goekkurt
et al. [12] studies, these 3 studies conflict with prior re-
ports by Srivastava et al. [11], and Terakura et al. [13].
Interestingly, the 3 negative studies were in people of
European descent, whereas the 2 positive studies
were in Asians, which may partially explain the dis-crepant results and suggests there are other factors re-
lated to the development of RRT. Most importantly,
all 3 studies of European-descent populations may
not have been powered to detect significant differences
given their relatively small sample sizes. The effect size
for our allogeneic BMT patients was much smaller
than that seen in our autologous BMT patients (1.26
versus 1.87, respectively, for theGSTM1/GSTT1 com-
parison), which combined with a smaller sample size,
led to inadequate statistical power. Unfortunately,
Goekkurt et al. [12] did not provide any risk estimates
or power calculations. Rocha et al. [25] did not provide
the effect sizes of their null results, but their smallest
significant effect size for the toxicity endpoints was
a hazard ratio of 2.2. It would be interesting to perform
a meta-analysis of individual patient data including
these 3 studies to determine if there is a significant as-
sociation of GSTM1/GSTT1 deletion polymorphisms
and toxicity after allogeneic BMT.
Although a higher rate of RRT after allogeneic
BMT was associated with the non-White race, we cau-
tion against generalizing this result because of the
smaller allogeneic cohort and the very small number
of non-Europeans (N5 14) in the allogeneic BMT pa-
tients. Because race is associated with RRT, this may
imply that the proportion of European, African, or
Asian ancestry in an individual’s genome may be asso-
ciated with RRT. However, to study this, it is neces-
sary to genotype Ancestry Informative Markers
(AIMs) to determine the ancestry proportions by
race, which was not feasible in our study with such
a small number of non-Europeans. The question could
be explored in a future study with a sufficient number
of patients of non-European descent.
Figure 1. Overall survival by genotype for autologous (A) and allogeneic (B) BMT patients. Thick line indicates GSTM1 and GSTT1 null genotype.
Dashed line indicates null genotype for either GSTM1 or GSTT1. Thin line indicates presence of both GSTM1 and GSTT1.
Biol Blood Marrow Transplant 16:801-808, 2010 807GSTM1 and Toxicity after BMTThe absence of common functional GST enzymes
yields a slower clearance of ROS, which may increase
the risk for end organ damage [26]. The lack of a sur-
vival benefit or detriment by GST genotype implies
that administering an intervention to reduce toxicity
based on GST genotype should not adversely affect
survival. Additional studies to confirm our first report
of the association of GSTM1 null genotype and toxic-
ity after autologous BMT and to further study the
mechanisms on the role of GST enzymes in endothe-
lial damage after chemotherapy and/or radiation treat-
ment are warranted.ACKNOWLEDGMENTS
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